Hyperhidrosis (HP:0000975)
Abnormal excessive perspiration (sweating) despite the lack of appropriate stimuli like hot and humid weather.
Synonyms: Increased sweating, Profuse sweating, Sweating, Sweating profusely, Sweating, increased, Excessive sweating, Diaphoresis
Comment: The terms hyperhidrosis and diaphoresis are often used interchangeably to describe excessive perspiration. Diaphoresis can be used to refer to excessive sweating that occurs with certain diseases (secondary hyperhidrosis). Since the HPO does not intend to provide coess for etiologies or diseases, we will use these terms interchangeably to refer to excessive perspiration without an appropriate cause such as hot and humid weather.
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Maturity onset diabetes of the young | 0.01293 | 0.08047 | 88.73 | 385.85 |
| 2 | Citrate cycle (TCA cycle) | 0.01490 | 0.08047 | 76.48 | 321.69 |
| 3 | Thyroid cancer | 0.01835 | 0.08258 | 61.59 | 246.23 |
| 4 | Transcriptional misregulation in cancer | 0.003922 | 0.05294 | 26.05 | 144.36 |
| 5 | Central carbon metabolism in cancer | 0.03446 | 0.1196 | 32.08 | 108.04 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | establishment of protein localization to telomere (GO:0070200) | 0.002498 | 0.03493 | 555.17 | 3326.77 |
| 2 | glial cell-derived neurotrophic factor receptor signaling pathway (GO:0035860) | 0.002498 | 0.03493 | 555.17 | 3326.77 |
| 3 | Schwann cell differentiation (GO:0014037) | 0.002498 | 0.03493 | 555.17 | 3326.77 |
| 4 | astrocyte development (GO:0014002) | 0.002997 | 0.03493 | 444.11 | 2580.41 |
| 5 | positive regulation of adenylate cyclase activity (GO:0045762) | 0.003495 | 0.03493 | 370.07 | 2093.27 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | four-way junction DNA binding (GO:0000400) | 0.00003048 | 0.0007162 | 332.92 | 3461.84 |
| 2 | Y-form DNA binding (GO:0000403) | 0.002498 | 0.01280 | 555.17 | 3326.77 |
| 3 | RNA-directed DNA polymerase activity (GO:0003964) | 0.002997 | 0.01280 | 444.11 | 2580.41 |
| 4 | telomerase activity (GO:0003720) | 0.002997 | 0.01280 | 444.11 | 2580.41 |
| 5 | phosphatidylethanolamine binding (GO:0008429) | 0.004492 | 0.01759 | 277.53 | 1500.17 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | transferase complex, transferring phosphorus-containing groups (GO:0061695) | 0.004492 | 0.03878 | 277.53 | 1500.17 |
| 2 | Ino80 complex (GO:0031011) | 0.006979 | 0.03878 | 170.74 | 847.70 |
| 3 | INO80-type complex (GO:0097346) | 0.01194 | 0.03878 | 96.46 | 427.12 |
| 4 | MLL1 complex (GO:0071339) | 0.01293 | 0.03878 | 88.73 | 385.85 |
| 5 | MLL1/2 complex (GO:0044665) | 0.01293 | 0.03878 | 88.73 | 385.85 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| NF1 | TRAMETINIB, BINIMETINIB, COBIMETINIB, DABRAFENIB, VEMURAFENIB |
| SDHC | – |
| RET | CABOZANTINIB, VANDETANIB |
| SDHAF2 | – |
| MAX | – |
| KIF1B | – |
| MEN1 | OLSALAZINE |
| TERT | OMACETAXINE MEPESUCCINATE |
| HNF4A | UREA |
| YY1 | – |
